Parvez Mantry, MD
Enriched profileMedical Director, Liver Institute Research; Medical Director, Hepatobiliary Tumor Program; Associate Program Director, Fellowship in Gastroenterology and Hepatology; Director of Scientific Affairs, Innovation and New Technology, Methodist Health System · Methodist Health System
Parvez Mantry is Medical Director, Liver Institute Research; Medical Director, Hepatobiliary Tumor Program; Associate Program Director, Fellowship in Gastroenterology and Hepatology; Director of Scientific Affairs, Innovation and New Technology, Methodist Health System at Methodist Health System. OpenAlex indexes 192 publications with 6,022 citations (h-index 32); ClinicalTrials.gov lists 16 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 13 Oct 2026
Parvez Mantry, MD, is Medical Director, Liver Institute Research at Methodist Health System / The Liver Institute (Methodist Dallas Medical Center), Dallas, TX. The public record shows 192 publications with 6,022 citations (h-index 32), centered on Liver Disease Diagnosis and Treatment, Hepatitis C virus research, Liver Disease and Transplantation. It also documents an investigator role on 16 registered clinical trials, industry payments reported by 45 companies.
- Most recent indexed publication: 2020 · Case reports in hepatology
- Top research focus: Liver Disease Diagnosis and Treatment
- 16 registered trials on ClinicalTrials.gov
- Open Payments reporting from 45 companies
Generated from the cited public record · current as of 13 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 1 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 54.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 13 Oct 2026
Listed as an investigator on 16 registered studies on ClinicalTrials.gov. The most recent:
- Analysis of Donor-derived Cell Free DNA in Liver Transplant Patients
Sponsor: Methodist Health System
Industry payments
Updated 13 Oct 2026
45 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Madrigal PharmaceuticalsProgram year202555 payments$103,930openpaymentsdata.cms.gov ↗
- Novo Nordisk IncProgram year202529 payments$73,810openpaymentsdata.cms.gov ↗
- Amgen Inc.Program year202559 payments$39,781openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
47.4%Bile Acid14.5%Ursodiol100%Part D≥50 patientsRifamycin Antibacterial7%Xifaxan100%Part D≥21 patients+ 11 more classes in this area
Cardiovascular
21.3%Aldosterone antagonist (MRA)9%Spironolactone100%Part D≥56 patientsLoop diuretic6.6%Furosemide100%Part D≥46 patients+ 3 more classes in this area
Cancer & immunology
18.2%Calcineurin inhibitor14.8%Tacrolimus100%Part D≥49 patientsPurine Antimetabolite1.8%Azathioprine100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 13 Oct 2026
15 congress contributions (2007–2026) across ADA, ASCO, ASTRO per OpenAlex. The most recent:
- Phase II study of tinengotinib in advanced cholangiocarcinoma: Analysis of molecular response and resistance mechanisms.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 13 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Morphological Characteristics of Biliary Strictures after Liver Transplantation Visualized Using SpyGlass™ Cholangioscopy.
Case reports in hepatology
Case Report2020
Most-cited works
by citation count (OpenAlex)Network
Updated 13 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 13 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/parvez-mantry-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/parvez-mantry-md-faasld-bab13760
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Parvez-Mantry-2047685459
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
backtable.com/shows/vi/contributors/dr-parvez-mantry
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →backtable.com ↗ - LinkedIn
linkedin.com/posts/methodist-health-system_congratulations-to-dr-parvez-mantry-on-the-activity-6458331680326377472-1CES
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - LinkedIn
LinkedIn: Parvez Mantry MD, FAASLD - The Liver Institute at Methodist Dallas Medical Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 13 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
L.T.M. Medical College, Bombay University, India
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →theliverinstitutetx.com ↗ - Residency in Internal Medicine
Metropolitan Hospital Center, New York Medical College
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →theliverinstitutetx.com ↗ - Fellowship in Gastroenterology and Hepatology
University of Rochester School of Medicine, New York
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →theliverinstitutetx.com ↗ - Board certified: Internal Medicine
Gastroenterology, and Transplant Hepatology (American Board of Internal Medicine)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →methodisthealthsystem.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →theliverinstitutetx.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →theliverinstitutetx.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →theliverinstitutetx.com ↗
Editorial & leadership roles
journal and society appointments- Site Principal Investigator
multiple hepatology/liver-disease clinical trials at Methodist Dallas Medical Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →theliverinstitutetx.com ↗
Secondary affiliations
appointments beyond the home institution- Formerly UNOS primary transplant physician and Director of Transplant Hepatology
University of Rochester Medical Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗ - Listed provider
Baylor Scott & White Health
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bswhealth.com ↗
Media & interviews
press, podcasts and appearances- Guest
BackTable VI Podcast Episode 127 - "Portal Hypertension & Ascites Management"
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →backtable.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hcplive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH